Strategic Initiative

Slingshot members are tracking this corporate initiative:

AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Under the terms of the new agreement, AstraZeneca and Moderna, a pioneer of mRNA Therapeutics™, have agreed to collaborate on two specific immuno-oncology programmes, based on promising pre-clinical data, including pharmacology in tumour models. Moderna will fund and be responsible for discovery and preclinical development of product candidates, with the aim of delivering one Investigational New Drug (IND) application-ready molecule for each of the two programmes. Moderna’s efforts will be led by its oncology-focused venture, Onkaido. AstraZeneca will be responsible for early clinical development, led by MedImmune, and Moderna and AstraZeneca will share the costs of late-stage clinical development. The two companies will co-commercialise resulting products in the US under a 50:50 profit sharing arrangement. AstraZeneca will lead ex-US commercialisation efforts, with Moderna receiving tiered royalties up to substantial double digits on ex-US sales.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jan 11, 2016
Projected Implementation:
Q1, 2016
Relevance Tracked Until:
Q1, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Rna Technology, Cancer, Mrna Platform, Protein Engineering, Collaboration, Immuno-oncology, Partnership, Co-commercialise, Co-develop, Ind, Onkaido